Pharma’s “reformulation playbook” is getting a new lease on life—and 505(b)(2) is the engine.
For years, the industry narrative has been simple: reformulation is innovation. But if you look closely at how the 505(b)(2) pathway is being used, a differen…

Drug spend is one of the few line items in healthcare that still behaves like a black box—until you turn it into a calendar.
That’s the core promise behind the procurement playbook in the DrugPatentWatch piece, “Patent Expiration Data: The Procurement …

The “Drug Patent Cliff” Isn’t Just a Pharma Story—It’s a Procurement Risk You Can Model
If you manage sourcing, contracting, or formulary strategy, you already know the uncomfortable truth: the biggest cost shocks in healthcare rarely arrive with a pre…

The Hidden IP Trap in Clinical Research: How Unvetted Software and AI Can Imperil Sponsor Patents
Clinical trials are supposed to be about evidence—data, safety, efficacy. But increasingly, the real risk isn’t only in the protocol. It’s in the software…

The “Hard 20” in New Zealand Isn’t Just a Legal Detail—It’s a Business Strategy
In drug development, timing is everything. But in New Zealand, timing is also structural.
A recent DrugPatentWatch deep dive on drug patents in New Zealand highlights a rea…

Pharma’s “Patent Box” moment is here—and it’s not just a tax footnote.
For years, life sciences executives treated IP as a scientific asset first and a financial lever second. But the global shift toward IP-linked tax regimes is changing the conversati…

Europe’s “divisional patent” trap is one of those legal mechanisms that sounds technical—until you realize what it can do to patients, payers, and competition.
At a high level, the strategy is simple: when a patent is challenged, a brand can use divisi…

Biopharma is in a talent race—and the winners will hire before the market even realizes it needs them.
Most people think the “patent-to-pipeline” journey is a science story. It’s not. It’s a people story.
Because in biopharma, the bottleneck rarely sho…